Table 1.
Patient characteristics. Clinical characteristics of 31 patients in whom an on-treatment biopsy could be obtained. Patient ID: SOR, sorafenib; ERL, erlotinib; DAS, dasatinib; VEM, vemurafenib; SUN, sunitinib; EVE, everolimus. Gender: M, male; F, female. Tumor type: HNSCC, head and neck squamous cell cancer; ACUP, adenocarcinoma of unknown primary origin; (pancreatic) NET, neuroendocrine tumor. Radiological response: SD, stable disease; C/P/MR, complete/partial/mixed response; PD, progressive disease; NE, not evaluable. pTyr phosphoproteomics could not be performed in 2 VEM patients: for VEM1, no pre-treatment tumor biopsy was taken; for VEM2, on-treatment tumor tissue was insufficient for pTyr profiling. On-treatment tumor drug concentration was determined in these patients.
| Patient ID | Gender, Age | Tumor Type | Biopsied Site | Skin Biopsy | Post-Study Treatment (Best Response) |
|---|---|---|---|---|---|
| SOR 1 | M, 69 | Hepatocellular | Liver | + | Sorafenib (SD) |
| SOR 2 | M, 65 | Melanoma | Subcutaneous | + | Dacarbazine (PD) |
| SOR 3 | M, 71 | Hepatocellular | Liver | + | Sorafenib (PD) |
| SOR 4 | M, 62 | Hepatocellular | Liver | + | Sorafenib (PD) |
| SOR 5 | F, 74 | Thyroid, papillary | Muscle | + | Sorafenib (SD) |
| ERL 1 | M, 53 | Pancreatic | Liver | + | FOLFIRINOX (NE) |
| ERL 2 | M, 57 | HNSCC | Subcutaneous | + | Cisplatin/5FU/cetuximab (MR) |
| ERL 3 | M, 71 | Pancreatic | Liver | + | FOLFIRINOX (SD) |
| ERL 4 | F, 48 | Rectal | Liver | + | CAPOX-B (PR) |
| ERL 5 | M, 68 | Esophageal | Liver | + | EOX (PR) |
| DAS 1 | M, 58 | Esophageal | Esophagus | + | Gemcitabine/cisplatin (SD) |
| DAS 2 | M, 69 | Colorectal | Liver | - | Cetuximab (NE, clinical PD) |
| DAS 3 | M, 62 | Prostate | Lymph node | + | Abirateron (SD) |
| DAS 4 | M, 72 | Colorectal | Chest wall | + | Irinotecan (PD) |
| DAS 5 | M, 67 | Melanoma | Subcutaneous | + | Vemurafenib (PR) |
| VEM 1 | F, 51 | Melanoma | Subcutaneous | + | Vemurafenib (SD) |
| VEM 2 | M, 77 | Melanoma | Lymph node | + | Vemurafenib (CR) |
| VEM 3 | M, 48 | Melanoma | Cutaneous | + | Vemurafenib (NE, clinical PD) |
| VEM 4 | M, 70 | Melanoma | Subcutaneous | + | Dabrafenib/trametinib (PR) |
| VEM 5 | M, 61 | Melanoma | Subcutaneous | + | Vemurafenib (PR) |
| VEM 6 | M, 82 | Melanoma | Lymph node | + | Dabrafenib (PR) |
| SUN 1 | F, 20 | Clear cell sarcoma | Lymph node | - | Doxorubicin (PD) |
| SUN 2 | M, 65 | ACUP | Subcutaneous | + | Gemcitabin/cisplatin (NE) |
| SUN 3 | M, 59 | Colorectal | Subcutaneous | - | CAPOX (NE) |
| SUN 4 | M, 62 | Colorectal | Lung | + | CAPOX-B (PR) |
| SUN 5 | M, 69 | Renal cell | Lymph node | + | Sunitinib (SD) |
| EVE 1 | M, 67 | Renal cell | Subcutaneous | - | Everolimus (SD) |
| EVE 2 | M, 57 | Renal cell | Adrenal gland | + | Everolimus/cyclophosphamide (SD) |
| EVE 3 | M, 74 | Renal cell | Subcutaneous | + | Sunitinib/dalteparin (PR) |
| EVE 4 | M, 75 | Pancreatic NET | Liver | + | Everolimus (SD) |
| EVE 5 | F, 51 | NET | Subcutaneous | + | Sandostatin (SD) |